Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California
Background and Aims With no report on the overall prevalence and ramifications of hepatitis Delta virus (HDV) infection in the United States for more than two decades, the characteristics of chronic hepatitis B virus (CHB) patients coinfected with HDV, including clinical presentation, rate of hepati...
Saved in:
Published in | Journal of gastroenterology and hepatology Vol. 28; no. 9; pp. 1521 - 1525 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Blackwell Publishing Ltd
01.09.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and Aims
With no report on the overall prevalence and ramifications of hepatitis Delta virus (HDV) infection in the United States for more than two decades, the characteristics of chronic hepatitis B virus (CHB) patients coinfected with HDV, including clinical presentation, rate of hepatitis C virus tri‐infection, and HDV viral load, were assessed.
Methods
At California Pacific Medical Center, a retrospective chart review was conducted on all CHB patients.
Results
Of 1191 CHB patients, 499 had been tested for HDV, with 42 (8%) determined to be coinfected; half of these were also hepatitis C virus‐infected. Cirrhosis was present in 73% of the coinfected, 80% of the tri‐infected, but only 22% of the monoinfected. Twenty‐nine patients (69%) were Caucasian non‐Hispanic; 10 (24%) were Asians and Pacific Islanders. Of 39 patients for whom HBV‐DNA quantification at time of HDV presentation was available, 22 (56%) had undetectable levels; four (10%) had levels > 100 000 IU/mL.
Conclusions
HDV affects individuals of all ages and various ethnic groups. Although HBV viral loads are lower, rates of cirrhosis are higher in coinfected patients and higher still in the tri‐infected. Our data support revising screening guidelines to advocate for all patients with HBV to be screened for HDV in order to both give the individual patient important information related to the possible need for treatment and to support the public health goal of reducing transmission by educating HDV‐negative patients about the need for protection against superinfection and HDV‐infected patients about the need to protect against transmission to others. |
---|---|
Bibliography: | CTSA ark:/67375/WNG-BK85DF00-D National Institutes of Health - No. UL1TR000100 California Pacific Medical Center Philanthropic Foundation istex:B6CA06A80A4E658CA7449C17BA3F9E40F79822A3 ArticleID:JGH12217 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
ISSN: | 0815-9319 1440-1746 |
DOI: | 10.1111/jgh.12217 |